Nachrichten zur Hims & Hers Health Inc. Aktie

A Fresh Look at Hims & Hers Health (HIMS) Valuation After Recent Share Price Volatility

Hims & Hers Health (HIMS) has captured some investor buzz lately as its stock price has moved over the past…

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth…

Hims & Hers Health Insider Sold Shares Worth $853,490, According to a Recent SEC Filing

Oluyemi Okupe, Chief Financial Officer, on November 17, 2025, sold 23,187 shares in Hims & Hers Health for $853,490.…

Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Competitive Challenges

Q3 Earnings Impact: Recent discussions on X about Hims & Hers Health (HIMS) have been lively following their third-quarter earnings…

Hims & Hers Enters Blood Testing Amid Preventive Health Surge

Hims & Hers has launched Labs, a subscription diagnostic service offering blood testing as consumers face rising healthcare costs.…

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS)

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

Chutes & Ladders— Former FDA official to lead policy at Hims & Hers; ATA CEO to retire in December

Welcome to this weeks Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please submit the…

Hims & Hers (HIMS) Investors Keep the Faith as Stock Slides 15%

If you only glance at the share price, you might think the Hims Hers Health ($HIMS) story has lost…

Hims & Hers faces pressure from GLP1 price war

Hims & Hers announced a $250 million share buyback program, but escalating GLP-1 price competition from Novo Nordisk overshadowed the…

Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy…

Commit To Purchase Hims & Hers Health At $20, Earn 27.2% Using Options

Investors eyeing a purchase of Hims & Hers Health Inc (Symbol: HIMS) shares, but tentative about paying the going market…

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine…

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine…

Hims & Hers Aktie: Kein Novo-Deal - Citi-Analyst bleibt skeptisch

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Citi:Daniel Grosslight, Analyst von Citi, vergibt für die Aktie von Hims &…

Hims & Hers: Telemedizin gewinnt im Winter an zusätzlicher Bedeutung

Hims & Hers hat sich in den USA zu einem Anbieter entwickelt, der Gesundheitsthemen entstaubt und über digitale Kanäle niedrigschwellig…

The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29%

Hims & Hers Health, Inc. ( NYSE:HIMS ) shares have had a horrible month, losing 29% after a relatively good…

Sell Rating for Hims & Hers Health Amid Pricing Pressures from Novo Nordisk’s GLP-1 Products

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health, retaining the price…

Telehealth Co. Hims Sued Over College Students Suicide

The family of a Washington State University student who died by suicide have sued telehealth company Hims & Hers Health…

Hims & Hers Health Shares Slide Amid Concerns

Hims & Hers Health ( ($HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual…

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

What Happened? Shares of telehealth company Hims & Hers Health NYSE:HIMS fell 4.9% in the afternoon session after news of…

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4.9% in the afternoon session after news of increased competition…

Hims & Hers Health stock rises after announcing $250 million buyback program

Hims & Hers Health, Inc. (NYSE:HIMS) saw its shares edge 1.5% higher on Monday after unveiling a fresh $250 million…

Hims & Hers names ex-FDA official Deb Autor as first policy chief

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government…

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

Stock screener for investors and traders, financial visualizations.…

Hims & Hers Health, Inc. Appoints Deb Autor as the First Chief Policy Officer

Hims & Hers Health, Inc. announced the appointment of Deb Autor as the company?s first Chief Policy Officer. In this…

Hims & Hers health authorizes $250 million share repurchase program

Hims & Hers Health (HIMS) has authorized a share repurchase program of up to $250 million of outstanding Class A…

Hims & Hers Health Announces New Share Buyback Program

Hims & Hers Health ( ($HIMS) ) has issued an announcement. On November 13, 2025, Hims & Hers Health, Inc.…

Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE)

Hims & Hers Health (HIMS) announced on Monday an up to $250M share repurchase program of outstanding class A common…

Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2%

Hims & Hers Health (HIMS) announced on Monday an up to $250M share repurchase program of outstanding class A common…

Hims & Hers Health stock rises after announcing $250 million buyback program By Investing.com

Hims & Hers Health stock rises after announcing $250 million buyback program…

Hims & Hers announces $250 million share repurchase program By Investing.com

Hims & Hers announces $250 million share repurchase program…

Hims & Hers Health stock rises after announcing $250 million buyback program By Investing.com

Hims & Hers Health stock rises after announcing $250 million buyback program…

Hims & Hers Health Announces New Share Repurchase Program

On November 13, 2025, Hims & Hers Health, Inc. announced a new $250 million share repurchase program. Key Highlights: …

Hims & Hers Health (NYSE: HIMS) sets $250M 3-year buyback after completing $100M program

Hims & Hers authorizes up to $250,000,000 in Class A share repurchases over three years, following a $100,000,000 plan, announced…

Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today…

Hims & Hers Health boosts access to personalized wellness with mobile app

US-based health and wellness platform Hims & Hers Health has launched Labs, offering customers a new way to understand their…

Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization

Supported by strong balance sheet, program provides flexibility for Company to capitalize on valuation disconnects over the next three years…

Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of…

Hims & Hers names ex-FDA official Deb Autor as first policy chief

(Reuters) -Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and…

Hims & Hers appoints former FDA leader Deb Autor as first CPO By Investing.com

Hims & Hers appoints former FDA leader Deb Autor as first CPO…

Hims & Hers appoints former FDA leader Deb Autor as first CPO By Investing.com

Hims & Hers appoints former FDA leader Deb Autor as first CPO…

Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor…

Hims & Hers (NYSE: HIMS) appoints Deb Autor Chief Policy Officer for global policy

Former FDA deputy commissioner Deb Autor will lead Hims & Hers global public policy, regulatory and government affairs and continues…

Hims & Hers Launches ‘Labs’ to Expand Into Data-Driven Diagnostics

Hims & Hers has rolled out Labs, a diagnostics platform offering up to 120 biomarker tests and personalized action plans…

Hims & Hers Health’s Valuation in Focus After Wrongful Death Lawsuit Raises New Questions

Hims & Hers Health is in the spotlight after the family of a Washington State University student filed a wrongful…

Why I’m Joining Hims & Hers

Hims & Hers Chief Policy Officer, Deb Autor, shares her perspective on the evolving healthcare landscape and how policy can…

Will Hims & Hers Healths (HIMS) Lab Partnership Shape Its Path to Recurring Revenue Leadership?

Earlier this month, Hims & Hers Health announced the launch of Labs, a direct-to-consumer laboratory testing platform in partnership with…

Does the Recent Pharmacy Partnership Signal a New Value Opportunity for Hims & Hers Health?

Wondering if Hims & Hers Health is a hidden gem or just generating buzz? Let’s dig into what’s driving all…

Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental Healthcare Violated Washington Law and Resulted in Son’s Death

SEATTLE, Nov. 14, 2025 (GLOBE NEWSWIRE) -- This week, the parents of Luke Tyler, the Washington State University (WSU) freshman…

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update

Hims & Hers Health (HIMS) Stock Falls as New ‘Labs’ Platform With Quest Diagnostics Launches – November 14, 2025 Update…